Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical India

Novartis To Consider “Off Shoring” Some Corporate Functions To India

  • News

Executive Summary

Novartis will consider "off shoring" certain corporate functions to India

You may also be interested in...



Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say

The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles

Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say

The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles

Clinical Trials Computerized Systems Guidance Issued; GSK Sees Savings

GlaxoSmithKline expects significant savings through the elimination of data managers as the company moves to computerize its clinical trial data, the company said

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical India
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS044395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By